Slovenský hematolologický portál - Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Michael Hallek,1 Bruce D. Cheson,2 Daniel Catovsky,3 Federico Caligaris-Cappio,4 Guillaume Dighiero,5 Hartmut Do¨hner,6 Peter Hillmen,7 Michael J. Keating,8 Emili Montserrat,9 Kanti R. Rai,10 and Thomas J. Kipps11
1Klinik I fu¨ r Innere Medizin, Universita¨ t zu Ko¨ ln, Ko¨ ln, Germany; 2Georgetown University Hospital, Lombardi Cancer Center, Washington, DC; 3Institute of Cancer Research, London, United Kingdom; 4Universita Vita-Salute Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Milano, Italy; 5Institute Pasteur, Montevideo, Uruguay; 6University of Ulm, Ulm, Germany; 7St James's Institute of Oncology, Leeds, United Kingdom; 8Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; 9Hospital Clinic, IDIBAPS, Barcelona, Spain; 10Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; and 11Rebecca and John Moores Cancer Center, University of California-San Diego, La Jolla

(Blood. 2008;111:5446-5456) © 2008 by The American Society of Hematology

Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the InternationalWorkshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

pozri guideline